TABLE OF CONTENTS

AMENDMENTS TO THE CLAIMS 3
REMARKS/ARGUMENTS 7
DISPOSITION OF CLAIMS 7
REJECTIONS UNDER 35 U.S.C. §103 7
CONCLUSION 8

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-58. (canceled)

59. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, which can produce an average steady-state plasma concentration of the antiviral drug greater than a therapeutically effective concentration of the antiviral drug over a period of about 4 hours to about 24 hours.

60. (canceled)

61. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 1 hour after oral administration.

62. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 12 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 4 hours after oral administration.

63. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, which can administer a therapeutically effective dose of the antiviral drug over a period of at least 24 hours after administration with no more than 30% by weight of the liquid antiviral drug composition being released within the first 12 hours after oral administration.

64-68. (canceled)

69. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, wherein the semipermeable layer comprises a semipermeable polymer and the expandable layer comprises a hydrophilic polymer.

70. (previously presented) The sustained release oral dosage form of claim 69, wherein the expandable layer further comprises a lubricant and/or an osmotically effective compound.

71. (previously presented) The sustained release oral dosage form of claim 70, wherein the hydrophilic polymer is present in an amount of up to 95 wt%, the osmotically effective compound is present in an amount of 0 wt% to 60 wt%, and the lubricant is present in an amount of 0 wt% to 5 wt% of the total composition of the expandable layer.

72. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, wherein the capsule is a gelatin capsule.

73-80. (canceled)

81. (currently amended) The sustained release oral dosage form of claim ~~76~~ 82, for use in treating a condition in a subject responsive to the antiviral drug, wherein said condition is acquired immune deficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV) infection in the subject.

82. (new) A sustained release oral dosage form comprising:
a capsule;

a liquid antiviral drug composition included in the capsule, the liquid antiviral drug composition comprising nelfinavir as an antiviral drug and polyoxyethylene 20 sorbitan monooleate as a solvent for the antiviral drug;

a semipermeable layer surrounding the external surface of the capsule;

an exit orifice for delivering the liquid antiviral drug composition from the capsule to an environment of use; and

an expandable layer positioned to push and displace the liquid antiviral drug composition from the capsule.

83. (new) The sustained release oral dosage form of claim 82, wherein nelfinavir is present in the liquid antiviral drug composition in an amount of about 50 wt% and polyoxyethylene 20 sorbitan monooleate is present in the liquid antiviral drug composition in an amount of about 50 wt%.

84. (new) The sustained release oral dosage form of claim 82, wherein the expandable layer is positioned within the capsule and remote from the exit orifice, and further comprising a barrier layer positioned between the expandable layer and the liquid antiviral drug formulation.

85. (new) The sustained release oral dosage form of claim 82, wherein the expandable layer is positioned between the capsule and the semipermeable layer, and further comprising a barrier layer positioned between the capsule and the expandable layer.

86. (new) The sustained release oral dosage form of claim 82, wherein the semipermeable membrane comprises cellulose acetate and polyoxypropylene glycol.

87. (new) The sustained release oral dosage form of claim 82, wherein the expandable layer comprises hydroxypropylmethylcellulose, sodium chloride, and sodium carboxymethylcellulose.

89. (new) A sustained release oral dosage form including a capsule, a semipermeable layer surrounding the capsule, an exit orifice for delivering material from the capsule to an environment of use, and an expandable layer for pushing and displacing material from the capsule, comprising:

a liquid antiviral drug composition included in the capsule, the liquid antiviral drug composition comprising nelfinavir as an antiviral drug and polyoxyethylene 20 sorbitan monooleate as a solvent for the antiviral drug.

90. (new) A sustained release oral dosage form comprising:

a capsule;

a liquid antiviral drug composition included in the capsule, the liquid antiviral drug composition comprising an antiviral drug dispersed in a liquid carrier composed of a liquid nonionic surfactant and a mono-,di-triglyceride, the antiviral drug being selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine, and zalcitabin;

a semipermeable layer surrounding the external surface of the capsule;

an exit orifice for delivering the liquid antiviral drug composition from the capsule to an environment of use; and

an expandable layer positioned to push and displace the liquid antiviral drug composition from the capsule.